董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Deval L. Patrick | 男 | Director | 63 | 未披露 | 未持股 | 2019-09-13 |
| Stephen Squinto | 男 | Director and Acting Head of Research and Development | 62 | 10.00万美元 | 未持股 | 2019-09-13 |
| Freda Lewis Hall | 女 | Director | 64 | 未披露 | 未持股 | 2019-09-13 |
| Jeffrey Schwartz | 男 | Director | 40 | 未披露 | 未持股 | 2019-09-13 |
| Saqib Islam | 男 | Chief Executive Officer and Director | 50 | 176.78万美元 | 未持股 | 2019-09-13 |
| Carl L. Gordon | 男 | Director | 54 | 未披露 | 未持股 | 2019-09-13 |
| Alan Fuhrman | 男 | Director | 63 | 未披露 | 未持股 | 2019-09-13 |
| Daniel S. Lynch | 男 | Chairman of the Board | 61 | 45.90万美元 | 未持股 | 2019-09-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Squinto | 男 | Director and Acting Head of Research and Development | 62 | 10.00万美元 | 未持股 | 2019-09-13 |
| Jens Renstrup | -- | Chief Medical Officer | 54 | 57.58万美元 | 未持股 | 2019-09-13 |
| Badreddin Edris | 男 | Chief Business Officer | 32 | 52.33万美元 | 未持股 | 2019-09-13 |
| L. Mary Smith | 女 | Senior Vice President, Clinical Research and Development | 52 | 未披露 | 未持股 | 2019-09-13 |
| Michael V. Greco | 男 | General Counsel and Secretary | 48 | 未披露 | 未持股 | 2019-09-13 |
| Saqib Islam | 男 | Chief Executive Officer and Director | 50 | 176.78万美元 | 未持股 | 2019-09-13 |
| Francis I. Perier, Jr. | 男 | Chief Financial Officer | 59 | 未披露 | 未持股 | 2019-09-13 |
董事简历
中英对照 | 中文 | 英文- Deval L. Patrick
-
Deval L. Patrick，自2021年2月起担任董事会成员。Patrick先生是私人影响力投资公司Vistria Group的高级合伙人，曾在2024年1月至2024年11月期间担任该公司的高级顾问。自2022年2月起，他一直担任哈佛大学肯尼迪学院公共领导实践教授和公共领导中心联合主任。2021年3月至2023年12月，Patrick先生担任贝恩资本有限责任公司的高级顾问，此前他曾在该公司创立，并于2015年4月至2019年12月担任Double Impact Fund的管理合伙人，这是一家专注于提供有竞争力的财务回报和积极社会影响的投资基金。此前，2007年1月至2015年1月，帕特里克先生担任马萨诸塞州联邦州长。Patrick先生自2021年1月起担任云通信开发者平台Twilio Inc.的董事会成员。他此前曾于2015年6月至2019年12月担任远程医疗技术公司American Well Corp.的董事会成员，并于2020年4月至2024年6月担任专注于神经科学的生物制药公司Cerevel Therapeutics Holdings, Inc.，该公司于2021年1月至2024年7月被艾伯维公司收购；Environmental Impact Acquisition Corp.是一家专注于可持续发展公司的特殊目的收购公司，于2021年1月至2022年2月担任该公司的董事会成员；以及全球血液疗法公司，一家专注于治疗镰状细胞病的生物技术公司，于2015年4月至2019年11月，以及从2020年5月开始直至2022年10月被辉瑞收购。此外，Patrick先生还担任多个慈善委员会的成员。Patrick先生拥有哈佛学院英美文学学士学位和哈佛法学院法学博士学位。
Deval L. Patrick,has been a member of Board since February 2021. Mr. Patrick is a Senior Partner of The Vistria Group, a private impact investment firm, having served as a Senior Advisor to the firm from January 2024 to November 2024. He has been a professor of the practice of public leadership and a co-director of the Center for Public Leadership at Harvard Kennedy School since February 2022. From March 2021 to December 2023, Mr. Patrick was a Senior Advisor at Bain Capital LLC, where he previously founded and, from April 2015 to December 2019, served as Managing Partner of the Double Impact Fund, an investment fund focused on delivering competitive financial returns and positive social impact. Previously, from January 2007 to January 2015, Mr. Patrick served as Governor of the Commonwealth of Massachusetts. Mr. Patrick has served on the boards of directors of Twilio Inc., a cloud communications developer platform, since January 2021. He previously served on the board of directors of American Well Corp., a telemedicine technology company, from June 2015 to December 2019, and from April 2020 to June 2024 Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company focused on neuroscience, from January 2021 until its acquisition by AbbVie Inc. in July 2024 Environmental Impact Acquisition Corp., a special purpose acquisition company focused on sustainability companies, from January 2021 to February 2022; and Global Blood Therapeutics, Inc., a biotech company focused on therapies to address sickle cell disease, from April 2015 to November 2019, and from May 2020 until its acquisition by Pfizer Inc. in October 2022. In addition, Mr. Patrick serves as a member of several charitable boards. Mr. Patrick holds a B.A. in English and American Literature from Harvard College and a J.D. from Harvard Law School. - Deval L. Patrick，自2021年2月起担任董事会成员。Patrick先生是私人影响力投资公司Vistria Group的高级合伙人，曾在2024年1月至2024年11月期间担任该公司的高级顾问。自2022年2月起，他一直担任哈佛大学肯尼迪学院公共领导实践教授和公共领导中心联合主任。2021年3月至2023年12月，Patrick先生担任贝恩资本有限责任公司的高级顾问，此前他曾在该公司创立，并于2015年4月至2019年12月担任Double Impact Fund的管理合伙人，这是一家专注于提供有竞争力的财务回报和积极社会影响的投资基金。此前，2007年1月至2015年1月，帕特里克先生担任马萨诸塞州联邦州长。Patrick先生自2021年1月起担任云通信开发者平台Twilio Inc.的董事会成员。他此前曾于2015年6月至2019年12月担任远程医疗技术公司American Well Corp.的董事会成员，并于2020年4月至2024年6月担任专注于神经科学的生物制药公司Cerevel Therapeutics Holdings, Inc.，该公司于2021年1月至2024年7月被艾伯维公司收购；Environmental Impact Acquisition Corp.是一家专注于可持续发展公司的特殊目的收购公司，于2021年1月至2022年2月担任该公司的董事会成员；以及全球血液疗法公司，一家专注于治疗镰状细胞病的生物技术公司，于2015年4月至2019年11月，以及从2020年5月开始直至2022年10月被辉瑞收购。此外，Patrick先生还担任多个慈善委员会的成员。Patrick先生拥有哈佛学院英美文学学士学位和哈佛法学院法学博士学位。
- Deval L. Patrick,has been a member of Board since February 2021. Mr. Patrick is a Senior Partner of The Vistria Group, a private impact investment firm, having served as a Senior Advisor to the firm from January 2024 to November 2024. He has been a professor of the practice of public leadership and a co-director of the Center for Public Leadership at Harvard Kennedy School since February 2022. From March 2021 to December 2023, Mr. Patrick was a Senior Advisor at Bain Capital LLC, where he previously founded and, from April 2015 to December 2019, served as Managing Partner of the Double Impact Fund, an investment fund focused on delivering competitive financial returns and positive social impact. Previously, from January 2007 to January 2015, Mr. Patrick served as Governor of the Commonwealth of Massachusetts. Mr. Patrick has served on the boards of directors of Twilio Inc., a cloud communications developer platform, since January 2021. He previously served on the board of directors of American Well Corp., a telemedicine technology company, from June 2015 to December 2019, and from April 2020 to June 2024 Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company focused on neuroscience, from January 2021 until its acquisition by AbbVie Inc. in July 2024 Environmental Impact Acquisition Corp., a special purpose acquisition company focused on sustainability companies, from January 2021 to February 2022; and Global Blood Therapeutics, Inc., a biotech company focused on therapies to address sickle cell disease, from April 2015 to November 2019, and from May 2020 until its acquisition by Pfizer Inc. in October 2022. In addition, Mr. Patrick serves as a member of several charitable boards. Mr. Patrick holds a B.A. in English and American Literature from Harvard College and a J.D. from Harvard Law School.
- Stephen Squinto
-
Stephen Squinto，从2015年4月起担任我们董事会成员。他目前担任OrbiMed（医疗投资公司）的投资合伙人，从2015年1月起在该公司工作。此前，联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.；1992年4月-2014年12月担任不同的职位，包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位，在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。
Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work. - Stephen Squinto，从2015年4月起担任我们董事会成员。他目前担任OrbiMed（医疗投资公司）的投资合伙人，从2015年1月起在该公司工作。此前，联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.；1992年4月-2014年12月担任不同的职位，包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位，在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。
- Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work.
- Freda Lewis Hall
-
Freda Lewis Hall自2019年11月以来一直担任我们的董事会成员。自2019年1月以来，Lewis-Hall博士一直担任制药公司辉瑞公司的首席病人官兼执行Vice President。从2009年到2019年1月，Lewis-Hall博士担任辉瑞首席医疗官。在2009年加入辉瑞之前，Lewis-Hall博士曾于2008年6月至2009年5月在生物制药公司Vertex Pharmaceuticals，Inc.和高级副总裁，U.S.Pharmaceuticals担任多个高级领导职位，包括首席医疗官和执行Vice President，Bristol-Myers Squibb Co.的医疗事务（从2003年到2008年5月）。自2017年8月以来，Lewis-Hall博士一直担任生物制药公司SpringWorksTherapeutics，Inc.的董事会成员。2014年12月至2017年5月，她担任梦百合服务公司泰尼特保健公司的董事会成员。Lewis-Hall博士在约翰霍普金斯大学（Johns Hopkins University）获得自然科学学士学位，在霍华德大学医学院（Howard University College of Medicine）获得医学博士学位。
Freda Lewis Hall,has served as a member of Conduit Pharmaceuticals Inc. Board since September 2023. She served as Senior Medical Advisor to the CEO of Pfizer Inc., or Pfizer, from December 2019 until her retirement in March 2020. Before assuming that responsibility, beginning January 2019, Dr. Lewis-Hall served as Chief Patient Officer and Executive Vice President of Pfizer. Dr. Lewis-Hall served as Pfizer's Chief Medical Officer from 2009 to January 2019. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held various senior leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals Incorporated from June 2008 to May 2009; Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008; Vice President Research and Development at Pharmacia Corporation from 2002-2003; Product Team Leader at Pharmacia and Eli Lilly and Company from 1998 to 2002; Director of Lilly Center for Women's Health from 1996-1999; and Clinical Research Physician at Eli Lilly from 1994 through 1996. In October 2021, Dr. Lewis-Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS), (where she serves as a member of the Nominating and Corporate Governance Committee); she serves as a member of the board of directors for Milliken & Company since July 2019, as a member of the Audit and HR and Compensation Committees; and as a member of the board of directors of SpringWorks Therapeutics, Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance Committee and as a member of the audit committee. Dr. Lewis-Hall served as a member of the board of directors for Exact Sciences Corporation (Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline Committees; a member of 1LifeHealthCare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC) from 2014 to 2017.Dr. Lewis-Hall holds an M.D. from Howard University College of Medicine and a B.A. in natural sciences from the Johns Hopkins University. - Freda Lewis Hall自2019年11月以来一直担任我们的董事会成员。自2019年1月以来，Lewis-Hall博士一直担任制药公司辉瑞公司的首席病人官兼执行Vice President。从2009年到2019年1月，Lewis-Hall博士担任辉瑞首席医疗官。在2009年加入辉瑞之前，Lewis-Hall博士曾于2008年6月至2009年5月在生物制药公司Vertex Pharmaceuticals，Inc.和高级副总裁，U.S.Pharmaceuticals担任多个高级领导职位，包括首席医疗官和执行Vice President，Bristol-Myers Squibb Co.的医疗事务（从2003年到2008年5月）。自2017年8月以来，Lewis-Hall博士一直担任生物制药公司SpringWorksTherapeutics，Inc.的董事会成员。2014年12月至2017年5月，她担任梦百合服务公司泰尼特保健公司的董事会成员。Lewis-Hall博士在约翰霍普金斯大学（Johns Hopkins University）获得自然科学学士学位，在霍华德大学医学院（Howard University College of Medicine）获得医学博士学位。
- Freda Lewis Hall,has served as a member of Conduit Pharmaceuticals Inc. Board since September 2023. She served as Senior Medical Advisor to the CEO of Pfizer Inc., or Pfizer, from December 2019 until her retirement in March 2020. Before assuming that responsibility, beginning January 2019, Dr. Lewis-Hall served as Chief Patient Officer and Executive Vice President of Pfizer. Dr. Lewis-Hall served as Pfizer's Chief Medical Officer from 2009 to January 2019. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held various senior leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals Incorporated from June 2008 to May 2009; Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008; Vice President Research and Development at Pharmacia Corporation from 2002-2003; Product Team Leader at Pharmacia and Eli Lilly and Company from 1998 to 2002; Director of Lilly Center for Women's Health from 1996-1999; and Clinical Research Physician at Eli Lilly from 1994 through 1996. In October 2021, Dr. Lewis-Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS), (where she serves as a member of the Nominating and Corporate Governance Committee); she serves as a member of the board of directors for Milliken & Company since July 2019, as a member of the Audit and HR and Compensation Committees; and as a member of the board of directors of SpringWorks Therapeutics, Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance Committee and as a member of the audit committee. Dr. Lewis-Hall served as a member of the board of directors for Exact Sciences Corporation (Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline Committees; a member of 1LifeHealthCare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC) from 2014 to 2017.Dr. Lewis-Hall holds an M.D. from Howard University College of Medicine and a B.A. in natural sciences from the Johns Hopkins University.
- Jeffrey Schwartz
-
Jeffrey Schwartz我们的首席执行官，于2004年加入贝恩资本，是贝恩资本生命科学公司投资团队的董事总经理和内部投资委员会的成员。在2016年共同创立贝恩资本生命科学（Bain Capital Life Sciences）之前，施瓦茨曾在贝恩资本私募股权的梦百合Vertical工作。Schwartz先生目前任职于Springworks Therapeutics NASDAQ:SWTX，Hugel（Kosdaq:145020）以及私人公司Gynesonics和Rapid Micro Biosystems的董事会，这是贝恩资本生命科学和私人公司QUVA Pharma的投资组合公司，后者是贝恩资本私募股权的投资组合公司。在加入贝恩资本之前，Schwartz先生于2000年至2004年在雷曼兄弟（Lehman Brothers）担任股票研究分析师。Schwartz先生在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位，在那里他是帕尔默学者，并在耶鲁大学（Yale University）以优异成绩获得经济学学士学位。
Jeffrey Schwartz,joined Bain Capital in 2004 and is the Chief Operating Officer of Bain Capital's Global Private Equity business. Prior to his current role, Mr. Schwartz co-founded and was a partner of its Life Sciences team from 2016 to2024. Prior to that, Mr. Schwartz was a member of Bain Capital's Private Equity team from 2004 to 2016, where he focused on healthcare investments. Mr. Schwartz previously served as an equity research analyst at Lehman Brothers, where he was focused on the aerospace and defense industries working in both New York and London. Mr. Schwartz has over 20 years of investing experience. Mr. Schwartz curretly serves on the board of directors of Rapid Micro Biosystems, Inc. (Nasdaq: RPID). Mr. Schwartz previously served on the board of directors of BCLS Acquisition Corp. (a special purpose acquisition company) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX). Mr. Schwartz graduated from Yale University where he majored in economics and received his M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. - Jeffrey Schwartz我们的首席执行官，于2004年加入贝恩资本，是贝恩资本生命科学公司投资团队的董事总经理和内部投资委员会的成员。在2016年共同创立贝恩资本生命科学（Bain Capital Life Sciences）之前，施瓦茨曾在贝恩资本私募股权的梦百合Vertical工作。Schwartz先生目前任职于Springworks Therapeutics NASDAQ:SWTX，Hugel（Kosdaq:145020）以及私人公司Gynesonics和Rapid Micro Biosystems的董事会，这是贝恩资本生命科学和私人公司QUVA Pharma的投资组合公司，后者是贝恩资本私募股权的投资组合公司。在加入贝恩资本之前，Schwartz先生于2000年至2004年在雷曼兄弟（Lehman Brothers）担任股票研究分析师。Schwartz先生在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位，在那里他是帕尔默学者，并在耶鲁大学（Yale University）以优异成绩获得经济学学士学位。
- Jeffrey Schwartz,joined Bain Capital in 2004 and is the Chief Operating Officer of Bain Capital's Global Private Equity business. Prior to his current role, Mr. Schwartz co-founded and was a partner of its Life Sciences team from 2016 to2024. Prior to that, Mr. Schwartz was a member of Bain Capital's Private Equity team from 2004 to 2016, where he focused on healthcare investments. Mr. Schwartz previously served as an equity research analyst at Lehman Brothers, where he was focused on the aerospace and defense industries working in both New York and London. Mr. Schwartz has over 20 years of investing experience. Mr. Schwartz curretly serves on the board of directors of Rapid Micro Biosystems, Inc. (Nasdaq: RPID). Mr. Schwartz previously served on the board of directors of BCLS Acquisition Corp. (a special purpose acquisition company) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX). Mr. Schwartz graduated from Yale University where he majored in economics and received his M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar.
- Saqib Islam
-
Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School. - Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
- Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School.
- Carl L. Gordon
-
Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
Carl L. Gordon,has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed since 1998. Dr. Gordon has served on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET) since 2015, ArriVent Biopharma, Inc. (Nasdaq: AVBP) since December 2022, Compass Therapeutics, Inc. (Nasdaq: CMPX) since September 2015, Keros Therapeutics, Inc. (Nasdaq: KROS) since March 2020, Kinnate Biopharma, Inc. (Nasdaq: KNTE) since December 2019, and Terns Pharmaceuticals, Inc. (Nasdaq: TERN) since October 2018, as well as several private companies. Dr. Gordon previously served on the boards of directors of Alector Inc. (Nasdaq: ALEC) from October 2013 to June 2019, Arsanis, Inc. (which merged with X4 Pharmaceuticals, Inc.) from January 2013 to March 2019, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) from November 2015 to November 2021, Passage Bio Inc. (Nasdaq: PASG) from September 2018 to February 2020, Prevail Therapeutics Inc. (acquired by Eli Lilly and Company) from October 2017 to January 2021, SpringWorks Therapeutics Inc. (Nasdaq: SWTX) from August 2017 to September 2019, Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) from June 2018 to February 2024 and Turning Point Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company) from May 2017 to November 2020.Dr. Gordon received a B.A. in Chemistry from Harvard University, a Ph.D. in molecular biology from the Massachusetts Institute of Technology and was a Postdoctoral Fellow at The Rockefeller University. - Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
- Carl L. Gordon,has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed since 1998. Dr. Gordon has served on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET) since 2015, ArriVent Biopharma, Inc. (Nasdaq: AVBP) since December 2022, Compass Therapeutics, Inc. (Nasdaq: CMPX) since September 2015, Keros Therapeutics, Inc. (Nasdaq: KROS) since March 2020, Kinnate Biopharma, Inc. (Nasdaq: KNTE) since December 2019, and Terns Pharmaceuticals, Inc. (Nasdaq: TERN) since October 2018, as well as several private companies. Dr. Gordon previously served on the boards of directors of Alector Inc. (Nasdaq: ALEC) from October 2013 to June 2019, Arsanis, Inc. (which merged with X4 Pharmaceuticals, Inc.) from January 2013 to March 2019, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) from November 2015 to November 2021, Passage Bio Inc. (Nasdaq: PASG) from September 2018 to February 2020, Prevail Therapeutics Inc. (acquired by Eli Lilly and Company) from October 2017 to January 2021, SpringWorks Therapeutics Inc. (Nasdaq: SWTX) from August 2017 to September 2019, Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) from June 2018 to February 2024 and Turning Point Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company) from May 2017 to November 2020.Dr. Gordon received a B.A. in Chemistry from Harvard University, a Ph.D. in molecular biology from the Massachusetts Institute of Technology and was a Postdoctoral Fellow at The Rockefeller University.
- Alan Fuhrman
-
Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University. - Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
- Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University.
- Daniel S. Lynch
-
Daniel S. Lynch，现为Xilio Therapeutics, Inc.的董事；2012年10月担任Omega Alpha SPAC的董事会主席。从2011年5月起，担任董事长，当时他加入Third Rock Ventures, L.P.，成为入驻企业家。2007年10月以来，他为多家私营的生物制药公司提供咨询服务、担任行政职务或董事，包括：Stromedix, Inc，直到2012年2月它被Biogen Idec收购； Avila Therapeutics, Inc. ，直到2012年2月，它被Celgene Corporation收购；BIND Biosciences, Inc；Eleven Biotherapeutics；RaNA Therapeutics；Nimbus Discovery, LLC；Edimer Pharmaceuticals；Ember Therapeutics；Blueprint Medicines。之前，他是ImClone Systems Corporation的首席执行官、首席财务官。作为首席执行官，他领导了该公司的成功转型，重塑辉煌，并确保了癌症新药ERBITUX （Cetuximab）通过FDA的审批；作为首席财务官，他领导了ImClone 、Bristol-Myers Squibb成立大型合资企业的谈判工作。职业生涯早期，他在Bristol-Myers Squibb工作了15年，担任过各种财务职位。他在U.S. Oncology担任了5年的董事、审核委员会成员，直到2010年12月它被McKesson收购。他在Wesleyan University获得数学学士学位，在Darden Graduate School of Business Administration at the University of Virginia获得工商管理硕士学位。
Daniel S. Lynch,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation by bluebird bio of its oncology portfolio and programs into 2seventy bio, which 2seventy Bio, Inc. refer to as the separation, Mr. Lynch served on the Board of Directors of bluebird bio. Mr. Lynch joined Google Ventures in 2021 as Executive Venture Partner and partners with life sciences CEOs and executives as a trusted advisor. As a coach and investor, he places deep emphasis on long-term relationships. Since 2007, Mr. Lynch has advised and served as an executive chair or member of the boards for multiple biopharmaceutical companies, including Stromedix (acquired by Biogen), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), Xilio Therapeutics, eGenesis Bio, BIND Biosciences, and Blueprint Medicines. Mr. Lynch currently serves on the board of SpringWorks Therapeutics. He also served as an entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. Previously, Mr. Lynch served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of the novel cancer treatment ERBITUX (Cetuximab). As CFO, Mr. Lynch led negotiations to form a major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for over 15 years. For five years, he served on the board of directors and the audit committee at U.S. Oncology, Inc. until its acquisition by McKesson in 2010. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at The University of Virginia. - Daniel S. Lynch，现为Xilio Therapeutics, Inc.的董事；2012年10月担任Omega Alpha SPAC的董事会主席。从2011年5月起，担任董事长，当时他加入Third Rock Ventures, L.P.，成为入驻企业家。2007年10月以来，他为多家私营的生物制药公司提供咨询服务、担任行政职务或董事，包括：Stromedix, Inc，直到2012年2月它被Biogen Idec收购； Avila Therapeutics, Inc. ，直到2012年2月，它被Celgene Corporation收购；BIND Biosciences, Inc；Eleven Biotherapeutics；RaNA Therapeutics；Nimbus Discovery, LLC；Edimer Pharmaceuticals；Ember Therapeutics；Blueprint Medicines。之前，他是ImClone Systems Corporation的首席执行官、首席财务官。作为首席执行官，他领导了该公司的成功转型，重塑辉煌，并确保了癌症新药ERBITUX （Cetuximab）通过FDA的审批；作为首席财务官，他领导了ImClone 、Bristol-Myers Squibb成立大型合资企业的谈判工作。职业生涯早期，他在Bristol-Myers Squibb工作了15年，担任过各种财务职位。他在U.S. Oncology担任了5年的董事、审核委员会成员，直到2010年12月它被McKesson收购。他在Wesleyan University获得数学学士学位，在Darden Graduate School of Business Administration at the University of Virginia获得工商管理硕士学位。
- Daniel S. Lynch,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation by bluebird bio of its oncology portfolio and programs into 2seventy bio, which 2seventy Bio, Inc. refer to as the separation, Mr. Lynch served on the Board of Directors of bluebird bio. Mr. Lynch joined Google Ventures in 2021 as Executive Venture Partner and partners with life sciences CEOs and executives as a trusted advisor. As a coach and investor, he places deep emphasis on long-term relationships. Since 2007, Mr. Lynch has advised and served as an executive chair or member of the boards for multiple biopharmaceutical companies, including Stromedix (acquired by Biogen), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), Xilio Therapeutics, eGenesis Bio, BIND Biosciences, and Blueprint Medicines. Mr. Lynch currently serves on the board of SpringWorks Therapeutics. He also served as an entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. Previously, Mr. Lynch served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of the novel cancer treatment ERBITUX (Cetuximab). As CFO, Mr. Lynch led negotiations to form a major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for over 15 years. For five years, he served on the board of directors and the audit committee at U.S. Oncology, Inc. until its acquisition by McKesson in 2010. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at The University of Virginia.
高管简历
中英对照 | 中文 | 英文- Stephen Squinto
Stephen Squinto，从2015年4月起担任我们董事会成员。他目前担任OrbiMed（医疗投资公司）的投资合伙人，从2015年1月起在该公司工作。此前，联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.；1992年4月-2014年12月担任不同的职位，包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位，在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。
Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work.- Stephen Squinto，从2015年4月起担任我们董事会成员。他目前担任OrbiMed（医疗投资公司）的投资合伙人，从2015年1月起在该公司工作。此前，联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.；1992年4月-2014年12月担任不同的职位，包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位，在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。
- Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work.
- Jens Renstrup
Jens Renstrup自2018年7月起担任首席医疗官。2015年6月至2018年4月，Renstrup博士担任亚力兄制药公司高级副总裁兼全球医疗事务主管在Alexion之前，Renstrup博士于2010年5月至2015年6月担任葛兰素史克全球医疗事务主管，并于2002年至2010年在Merck&Co.担任多个医疗总监职位。Renstrup博士拥有哥本哈根大学（University of Copenhagen）的医学博士学位和哥本哈根商学院（Copenhagen Business School）的市场营销研究生文凭。
Jens Renstrup has served as our Chief Medical Officer since July 2018. From June 2015 to April 2018 Dr. Renstrup was Senior Vice President and Head of Global Medical Affairs at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Renstrup served as Head of Global Medical Affairs at GlaxoSmithKline from May 2010 to June 2015 and held various medical director positions at Merck & Co. from 2002 to 2010. Dr. Renstrup holds an M.D. from the University of Copenhagen and a graduate diploma in marketing from Copenhagen Business School.- Jens Renstrup自2018年7月起担任首席医疗官。2015年6月至2018年4月，Renstrup博士担任亚力兄制药公司高级副总裁兼全球医疗事务主管在Alexion之前，Renstrup博士于2010年5月至2015年6月担任葛兰素史克全球医疗事务主管，并于2002年至2010年在Merck&Co.担任多个医疗总监职位。Renstrup博士拥有哥本哈根大学（University of Copenhagen）的医学博士学位和哥本哈根商学院（Copenhagen Business School）的市场营销研究生文凭。
- Jens Renstrup has served as our Chief Medical Officer since July 2018. From June 2015 to April 2018 Dr. Renstrup was Senior Vice President and Head of Global Medical Affairs at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Renstrup served as Head of Global Medical Affairs at GlaxoSmithKline from May 2010 to June 2015 and held various medical director positions at Merck & Co. from 2002 to 2010. Dr. Renstrup holds an M.D. from the University of Copenhagen and a graduate diploma in marketing from Copenhagen Business School.
- Badreddin Edris
Badreddin Edris自2021年2月以来一直担任我们的董事会成员。Edris博士共同创立了公司，自2018年3月起担任我们的战略顾问，并于2017年5月至2018年3月担任运营职务。Edris博士自2021年1月起担任临床阶段生物制药公司SpringWorksTherapeutics，Inc.的首席运营官，此前曾于2018年9月至2020年12月担任Springworks的首席商务官。此前，Edris博士曾于2014年6月至2018年11月担任梦百合投资公司OrbiMed Advisors LLC私募股权团队的投资和运营专业人士。在OrbiMed期间，Edris博士还在OrbiMed投资组合公司SilverbackTherapeutics，Inc.共同创立并担任运营职务，他于2016年4月至2018年3月担任公司发展主管，并于2018年4月至2018年9月担任首席商务官。在OrbiMed之前，Edris博士是贝恩公司（Bain&Co Inc.）梦百合业务的管理顾问。Edris博士在韦伯州立大学（Weber State University）获得微生物学学士学位，在斯坦福大学（Stanford University）获得生物学硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得遗传学博士学位，他是该校的国家科学基金会研究生研究员。
Badreddin Edris,co-founded the Company and served in an operational role from May 2017 until March 2018 before transitioning into an advisory role. Since January 2021, Dr. Edris has been the Chief Operating Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and was previously the Chief Business Officer of SpringWorks from September 2018 to December 2020. Previously, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm, from June 2014 to November 2018. While at OrbiMed, Dr. Edris also co-founded and held an operating role at Silverback Therapeutics, Inc., an OrbiMed portfolio company, where he was Head of Corporate Development from April 2016 to March 2018 and Chief Business Officer from April 2018 to September 2018. Before OrbiMed, Dr. Edris was a management consultant in the healthcare practice at Bain & Co Inc. Dr. Edris received a B.I.S. in microbiology from Weber State University, a M.S. in biology from Stanford University and a Ph.D. in genetics from Stanford University School of Medicine, where he was a National Science Foundation Graduate Research Fellow.- Badreddin Edris自2021年2月以来一直担任我们的董事会成员。Edris博士共同创立了公司，自2018年3月起担任我们的战略顾问，并于2017年5月至2018年3月担任运营职务。Edris博士自2021年1月起担任临床阶段生物制药公司SpringWorksTherapeutics，Inc.的首席运营官，此前曾于2018年9月至2020年12月担任Springworks的首席商务官。此前，Edris博士曾于2014年6月至2018年11月担任梦百合投资公司OrbiMed Advisors LLC私募股权团队的投资和运营专业人士。在OrbiMed期间，Edris博士还在OrbiMed投资组合公司SilverbackTherapeutics，Inc.共同创立并担任运营职务，他于2016年4月至2018年3月担任公司发展主管，并于2018年4月至2018年9月担任首席商务官。在OrbiMed之前，Edris博士是贝恩公司（Bain&Co Inc.）梦百合业务的管理顾问。Edris博士在韦伯州立大学（Weber State University）获得微生物学学士学位，在斯坦福大学（Stanford University）获得生物学硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得遗传学博士学位，他是该校的国家科学基金会研究生研究员。
- Badreddin Edris,co-founded the Company and served in an operational role from May 2017 until March 2018 before transitioning into an advisory role. Since January 2021, Dr. Edris has been the Chief Operating Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and was previously the Chief Business Officer of SpringWorks from September 2018 to December 2020. Previously, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm, from June 2014 to November 2018. While at OrbiMed, Dr. Edris also co-founded and held an operating role at Silverback Therapeutics, Inc., an OrbiMed portfolio company, where he was Head of Corporate Development from April 2016 to March 2018 and Chief Business Officer from April 2018 to September 2018. Before OrbiMed, Dr. Edris was a management consultant in the healthcare practice at Bain & Co Inc. Dr. Edris received a B.I.S. in microbiology from Weber State University, a M.S. in biology from Stanford University and a Ph.D. in genetics from Stanford University School of Medicine, where he was a National Science Foundation Graduate Research Fellow.
- L. Mary Smith
L.Mary Smith自2017年8月起担任我们的高级副总裁，临床研究与开发。在加入我们之前，史密斯博士于2016年6月至2017年8月担任辉瑞（Pfizer）全资子公司Bamboo Therapeutics，Inc.临床开发执行Vice President。在加入Bamboo之前，史密斯博士于2005年至2016年在United Therapeutics Corporation研究与开发部门担任越来越重要的职务，最近于2014年12月至2016年6月担任产品开发Vice President。她在新罕布什尔大学（University of New Hampshire）获得生物化学学士学位和微生物学博士学位，并在埃默里大学（Emory University）接受博士后培训。
L. Mary Smith has served as our Senior Vice President, Clinical Research and Development since August 2017. Prior to joining us, Dr. Smith was the Executive Vice President of Clinical Development at Bamboo Therapeutics, Inc., a wholly owned subsidiary of Pfizer, from June 2016 to August 2017. Prior to joining Bamboo, Dr. Smith held positions of increasing responsibility in the research and development department at United Therapeutics Corporation from 2005 to 2016 most recently as Vice President of Product Development from December 2014 to June 2016. She earned a B.S. in biochemistry and a Ph.D. in microbiology from the University of New Hampshire, and she received her postdoctoral training at Emory University.- L.Mary Smith自2017年8月起担任我们的高级副总裁，临床研究与开发。在加入我们之前，史密斯博士于2016年6月至2017年8月担任辉瑞（Pfizer）全资子公司Bamboo Therapeutics，Inc.临床开发执行Vice President。在加入Bamboo之前，史密斯博士于2005年至2016年在United Therapeutics Corporation研究与开发部门担任越来越重要的职务，最近于2014年12月至2016年6月担任产品开发Vice President。她在新罕布什尔大学（University of New Hampshire）获得生物化学学士学位和微生物学博士学位，并在埃默里大学（Emory University）接受博士后培训。
- L. Mary Smith has served as our Senior Vice President, Clinical Research and Development since August 2017. Prior to joining us, Dr. Smith was the Executive Vice President of Clinical Development at Bamboo Therapeutics, Inc., a wholly owned subsidiary of Pfizer, from June 2016 to August 2017. Prior to joining Bamboo, Dr. Smith held positions of increasing responsibility in the research and development department at United Therapeutics Corporation from 2005 to 2016 most recently as Vice President of Product Development from December 2014 to June 2016. She earned a B.S. in biochemistry and a Ph.D. in microbiology from the University of New Hampshire, and she received her postdoctoral training at Emory University.
- Michael V. Greco
MichaelV.Greco自2018年6月起担任我们的总法律顾问兼秘书。在加入我们之前，Greco先生于2007年2月至2018年6月在亚力兄制药公司法律部门担任越来越重要的职务，最近于2015年8月至2018年6月担任法律高级副总裁兼公司秘书。任职Alexion公司之前，他曾担任Wiggin and Dana LLP（从2005年5月到2007年2月）、Bingham McCutchen LLP（现称为Morgan，Lewis&Bockius LLP）的公司和交易律师（从1999年9月到2005年5月）。在进入法学院之前，Greco先生曾在美国陆军工程兵部队（U.S.Army Corps of Engineers）服役。他在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在西点军校（United States Military Academy，West Point）获得工商管理硕士学位。
Michael V. Greco has served as our General Counsel and Secretary since June 2018. Prior to joining us, Mr. Greco held positions of increasing responsiblity in the legal department at Alexion Pharmaceuticals, Inc. from February 2007 until June 2018 most recently as Senior Vice President of Law and Corporate Secretary from August 2015 to June 2018. Prior to Alexion, he was a corporate and transactional attorney at Wiggin and Dana LLP from May 2005 to February 2007 and Bingham McCutchen LLP now Morgan, Lewis & Bockius LLP from September 1999 to May 2005. Prior to attending law school, Mr. Greco served in the U.S. Army Corps of Engineers. He received a J.D. from Suffolk University Law School and a B.S. from the United States Military Academy, West Point.- MichaelV.Greco自2018年6月起担任我们的总法律顾问兼秘书。在加入我们之前，Greco先生于2007年2月至2018年6月在亚力兄制药公司法律部门担任越来越重要的职务，最近于2015年8月至2018年6月担任法律高级副总裁兼公司秘书。任职Alexion公司之前，他曾担任Wiggin and Dana LLP（从2005年5月到2007年2月）、Bingham McCutchen LLP（现称为Morgan，Lewis&Bockius LLP）的公司和交易律师（从1999年9月到2005年5月）。在进入法学院之前，Greco先生曾在美国陆军工程兵部队（U.S.Army Corps of Engineers）服役。他在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在西点军校（United States Military Academy，West Point）获得工商管理硕士学位。
- Michael V. Greco has served as our General Counsel and Secretary since June 2018. Prior to joining us, Mr. Greco held positions of increasing responsiblity in the legal department at Alexion Pharmaceuticals, Inc. from February 2007 until June 2018 most recently as Senior Vice President of Law and Corporate Secretary from August 2015 to June 2018. Prior to Alexion, he was a corporate and transactional attorney at Wiggin and Dana LLP from May 2005 to February 2007 and Bingham McCutchen LLP now Morgan, Lewis & Bockius LLP from September 1999 to May 2005. Prior to attending law school, Mr. Greco served in the U.S. Army Corps of Engineers. He received a J.D. from Suffolk University Law School and a B.S. from the United States Military Academy, West Point.
- Saqib Islam
Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School.- Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
- Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School.
- Francis I. Perier, Jr.
Francis I. Perier, Jr.，自2010十二月三十一日起，担任财务管理执行副总裁，公司的首席财务官。之前，2004九月至2010十二月，他担任财务高级副总裁；2004九月起，担任公司首席财务官。从2004三月到2004九月加入公司之前，他担任Bristol-Myers Squibb的财务，业务规划，美洲药物部副总裁。2004三月之前的8年里，他一直担任 Bristol-Myers Squibb的高级财务职位，包括在ConvaTec分部担任财务规划，业务发展，信息技术副总裁的4年经历。在这之前，他曾是德勤会计师事务所合伙人。
Francis I. Perier, Jr. has served as Springworks Therapeutics, Inc.'s Chief Financial Officer since August 2019. Prior to joining SpringWorks, Mr. Perier was retired following the 2014 acquisition of Forest Laboratories, Inc. by Actavis. From September 2004 to October 2014 Mr. Perier served as Chief Financial Officer of Forest Laboratories, Inc. Prior to Forest, Mr. Perier was with Bristol-Myers Squibb from 1995 to 2004 where he worked in corporate and operations executive finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning-Americas Medicines Group, the company's largest business unit at that time. Before joining Bristol-Myers Squibb, Mr. Perier served as an accounting and auditing partner at Deloitte, where he worked for approximately 15 years. Mr. Perier also served as a member of the board of directors of Concordia International, Inc., a specialty pharmaceutical company from May 2017 until September 2018. Mr. Perier received an M.B.A. from the Stern School of Business, New York University and a Bachelor's degree in Accountancy from Villanova University. He is a Certified Public Accountant inactive and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.- Francis I. Perier, Jr.，自2010十二月三十一日起，担任财务管理执行副总裁，公司的首席财务官。之前，2004九月至2010十二月，他担任财务高级副总裁；2004九月起，担任公司首席财务官。从2004三月到2004九月加入公司之前，他担任Bristol-Myers Squibb的财务，业务规划，美洲药物部副总裁。2004三月之前的8年里，他一直担任 Bristol-Myers Squibb的高级财务职位，包括在ConvaTec分部担任财务规划，业务发展，信息技术副总裁的4年经历。在这之前，他曾是德勤会计师事务所合伙人。
- Francis I. Perier, Jr. has served as Springworks Therapeutics, Inc.'s Chief Financial Officer since August 2019. Prior to joining SpringWorks, Mr. Perier was retired following the 2014 acquisition of Forest Laboratories, Inc. by Actavis. From September 2004 to October 2014 Mr. Perier served as Chief Financial Officer of Forest Laboratories, Inc. Prior to Forest, Mr. Perier was with Bristol-Myers Squibb from 1995 to 2004 where he worked in corporate and operations executive finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning-Americas Medicines Group, the company's largest business unit at that time. Before joining Bristol-Myers Squibb, Mr. Perier served as an accounting and auditing partner at Deloitte, where he worked for approximately 15 years. Mr. Perier also served as a member of the board of directors of Concordia International, Inc., a specialty pharmaceutical company from May 2017 until September 2018. Mr. Perier received an M.B.A. from the Stern School of Business, New York University and a Bachelor's degree in Accountancy from Villanova University. He is a Certified Public Accountant inactive and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.